#USA #New York #Securities Class Action #GeneDx Holdings #WGS

Shareholder Alert: GeneDx Holdings Corp. Class Action Lawsuit

Investors in GeneDx Holdings Corp. (NASDAQ: WGS) have an important deadline approaching. Those who bought securities between April 16, 2025, and May 4, 2026, have until August 3, 2026, to move forward as lead plaintiffs in a class action lawsuit. This lawsuit arises from a recent significant drop in WGS shares, which fell by $33.42, or approximately 49.20%. The decline followed the company's announcement of a $31.2 million impairment loss related to its Fabric Genomics acquisition and a slashed revenue forecast for the year by roughly $65 million.

What Does Being a Lead Plaintiff Mean?

Under the Private Securities Litigation Reform Act of 1995, one investor or a small group of investors is appointed as the lead plaintiff for a class action lawsuit. This individual or group will guide the litigation on behalf of all members affected by the alleged wrongdoing. In the GeneDx case, it revolves around claims that the company made materially false statements regarding its Fabric Genomics acquisition during the specified time frame leading up to the decline in share value.

Criteria for Lead Plaintiff

The selection process for the lead plaintiff is straightforward. The one who has the largest financial loss from investments in WGS shares within the class period typically takes on this role. Notably, there is no minimum loss requirement to apply. As long as you purchased shares during the class period, you can be considered for the position.

Importantly, lead plaintiffs do not incur any out-of-pocket costs; instead, legal teams operate on a contingency scenario that must be approved by the court. Serving as a lead plaintiff won’t increase an individual’s recovery but will provide them with insight and oversight into the strategy and settlement parameters of the case.

Investors not looking to be lead plaintiffs remain class members and can still participate in any settlements or recoveries that arise from the outcome of the lawsuit. After the deadline passes, the court will consolidate competing motions for lead plaintiff and decide based on who best meets the PSLRA's criteria.

Post-Deadline Process and Rights of Absent Class Members

Once the August 3, 2026 deadline has passed, the court will undertake a process that often takes weeks to determine the most suitable lead plaintiff from those who apply. At this stage, once a lead plaintiff is appointed, they will also have the authority to choose lead counsel for the case, which then progresses to the pleading stage.

However, it’s crucial for investors who do not apply for lead plaintiff status to understand their rights. They maintain their status as absent class members and do not need to take any action before August 3, 2026, to ensure that they can participate in any future settlement or judgment. Applying for the lead status is only necessary for those wanting to represent the class.

Importance of the Lead Plaintiff

The lead plaintiff role is key in ensuring that the interests of shareholders with considerable stakes in the outcome are represented. In this case, the sharp drop in the investment value has made it even more vital to select a lead plaintiff who has experienced substantial losses resulting from GeneDx's actions. As Joseph E. Levi, an attorney on the case, noted, ensuring the class's representation by an engaged lead plaintiff is particularly significant in scenarios where investors have experienced considerable financial damage.

If you believe you meet the criteria or want to understand more about your potential recovery, contact Joseph E. Levi at (888) SueWallSt for an assessment of your losses. It could pave the way for participation in the upcoming recovery efforts stemming from the GeneDx investigation.

This lawsuit serves as a crucial reminder for investors about the importance of diligence and timely action in the wake of financial losses in the stock market.